| ￥3300 | |
| Z05133-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 57.6 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 110-115 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized CD42b/GP1BA, His, Human, His Tag at 1 μg /ml (100 μl/well) on the plate. Dose response curve for Anti-CD42b Antibody, hFc Tag with the EC50 of 6.2ng/ml determined by ELISA. »
The purity of CD42b/GP1BA, His, Human is greater than 95% as determined by SEC-HPLC. »
CD42b/GP1BA, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Absence of the CD42 complex leads to the Bernard-Soulier syndrome (BSS), which is a bleeding disorder characterized by thrombocytopenia and giant platelets. So far, mutations have been found in the genes encoding CD42a, CD42b and CD42c in patients with BSS**. |
| Synonyms | GP-Ib alpha; GPIb-alpha; GPIbA; GP1BA; BDPLT1; BDPLT3; BSS; CD42B; CD42b-alpha; DBPLT3; GP1B; VWDP; BP1BA; MGC34595 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
